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OBJECTIVE: To investigate a possible direct, growth hormone-releasing, hormone-independent action of a growth
hormone secretagogue, GHRP-2, in pituitary somatotroph cells in the presence of inactive growth hormone-
releasing hormone receptors.
MATERIALS AND METHODS: The responses of serum growth hormone to acutely injected growth hormone-releasing
P-2 in lit/lit mice, which represent a model of GH deficiency arising frommutated growth hormone-releasing hormone-
receptors, were compared to those observed in the heterozygous (lit/+) littermates and wild-type (+/+) C57BL/6J mice.
RESULTS: After the administration of 10 mcg of growth hormone-releasing P-2 to lit/lit mice, a growth hormone
release of 9.3¡1.5 ng/ml was observed compared with 1.04¡1.15 ng/ml in controls (p,0.001). In comparison, an
intermediate growth hormone release of 34.5¡9.7 ng/ml and a higher growth hormone release of 163¡46 ng/ml
were induced in the lit/+ mice and wild-type mice, respectively. Thus, GHRP-2 stimulated growth hormone in the lit/
lit mice, and the release of growth hormone in vivo may be only partially dependent on growth hormone-releasing
hormone. Additionally, the plasma leptin and ghrelin levels were evaluated in the lit/lit mice under basal and
stimulated conditions.
CONCLUSIONS: Here, we have demonstrated that lit/lit mice, which harbor a germline mutation in the Growth
hormone-releasing hormone gene, maintain a limited but statistically significant growth hormone elevation after
exogenous stimulation with GHRP-2. The present data probably reflect a direct, growth hormone-independent
effect on Growth hormone S (ghrelin) stimulation in the remaining pituitary somatotrophs of little mice that is
mediated by growth hormone S-R 1a.
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INTRODUCTION
The synthesis and secretion of growth hormone (GH) are
primarily regulated by the hypothalamic hormones GH-
releasing hormone (GHRH) and somatostatin by the negative
feedback of GH and IGF-I and by the natural endogenous
GH-releasing hormone ghrelin (1-8). Normal somatotroph
maturation, proliferation, and somatic growth and develop-
ment require GHRH (9). In the late differentiation phases of
somatotroph cells, GHRH activates Gs alpha, cAMP, and the
protein kinase A pathway through its cell membrane receptor
GHRH-R (1,10,11). Conversely, ghrelin, which was initially
isolated from the rat stomach and hypothalamus, acts
through the growth hormone secretagogue (GHS) receptor
(GHS-R 1a), which is coupled to members of the Gq/i family
and activates phospholipase C (2,12,13).
Synthetic GHSs are ghrelin receptor agonists that stimu-
late GH secretion in vitro and in vivo. They include GH-
releasing peptides (GHRPs), such as GHRP-2, and non-
peptide compounds. Synthetic GHSs and ghrelin also
stimulate ACTH/cortisol and prolactin release via hypotha-
lamic effects and have been shown to increase food intake,
energy expenditure, sleep and cardiac tone (15-17).
Although their chemical structures vary, all GHSs seem to
act through the GHS-R to enhance GH secretion and food
intake. GHS-R mRNA has been identified in the pituitary
gland, arcuate nucleus of the hypothalamus, and in other
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tissues (6,15-17). For maximal GH stimulation, GHRPs
require a simultaneous secretion of hypothalamic GHRH
(18-21). Furthermore, ghrelin and synthetic GHSs potentiate
GHRH-induced cAMP production and increase the levels
of several GHRH-Rs, which may also result in altered
interactions between GHS-R and GHRH (22-25). In this
context, a dual and complementary action of ghrelin and
GHRP on the hypothalamus and pituitary gland may occur.
Furthermore, a paracrine effect on the arcuate nucleus of the
hypothalamus, which is involved in food intake and energy
expenditure regulation, should be mentioned (17).
The predominant site of action of GHSs for GH secretion
has not been fully established. GHS-Rs have been identified
in both the pituitary gland and the hypothalamus, and
GHSs may act at either or both sites. Some evidence
indicates that the GH-secreting action of GHSs and ghrelin
may occur mainly in the hypothalamus, with a marginal
direct effect on the pituitary gland (25-27). Accordingly, a
limited but statistically significant GH elevation (p,0.05)
was first documented following an acute stimulus with
GHRP2 in GH-deficient patients with short stature resulting
from a germline mutation in the GHRH-R gene (28). Soon
after, other studies supported these initial findings (29,30),
which indicates a direct action of GHRP-2 in the pituitary
gland. The cloning of the mouse and human growth
hormone-releasing hormone receptor gene (ghrhr) was
accomplished following the finding that different mutations
analogous to the ghrhr Asp60Gly inactivating mutation of
GH-deficient little mice also occurred in GH-deficient
humans (31-37). The ghrhr mutation in lit/lit mice resulted
in a complete lack of GHRH-mediated GH release, which
was further supported by the finding that the mutated
GHRH-R protein did not bind to GHRH (32,33). As
expected, the complete lack of a GH response to GHRH1-
29NH2 has been reported in little mice (38-40). The complete
lack of a GH response to GHRP-6 was also reported in little
mice (41). Nevertheless, because GHSs act specifically
through the GHS-R, it is reasonable to assume that a GH
response may occur in response to a GHS challenge in little
mice. In support of this hypothesis, GHRP-2 has been
shown to increase the GH release from rat pituitaries in
vitro, even after the GHRH-R was blocked using the
antisense oligonucleotide approach (42).
The little mouse is an established animal model for
assessing the direct GHRH-independent effects of GHSs
and ghrelin on pituitary somatotroph cells (33-35). Here we
evaluated the GH response to GHRP-2 in little mice (lit/lit),
their heterozygous (lit/+) littermates, and wild-type (+/+)
controls. Additionally, a possible role of GHRH and GHRH-
R on the secretion and action of ghrelin was evaluated by
measuring the fasting and fed plasma ghrelin and serum
leptin levels in these animals.
MATERIALS AND METHODS
Animals and housing conditions
Little mice (C57BL/6J lit/lit) and their heterozygous (lit/
+) littermates were purchased from The Jackson Laboratory
(Bar Harbor, ME, USA), and a breeding colony was
established in our animal house (43). Mutant mice were
produced by mating C57BL/6J lit/lit females to C57BL/6J
lit/+ males. Mice of both sexes at 45-90 days of age were
used in the assays. As controls, wild-type (+/+) C57BL mice,
obtained from the Tropical Medicine Division, University of
Sa˜o Paulo School of Medicine (Sa˜o Paulo, Brazil), were used
at 45-90 days of age (body weight ,30 g). The body weights
of the lit/lit and lit/+ mice were approximately 10-12 g and
20-25 g, respectively, at the same age and were obtained by
a sensitive method (43).
The mice were maintained in an air-conditioned room at a
temperature of 24¡1 C˚. Water and food were provided ad
libitum, and light was regulated on a 12-h light/12-h dark
schedule.
A group of mice was kept under fasting conditions by
removing food in the afternoon at approximately 17:00 h.
Blood was collected from the fasted and non-fasted mice
groups the following day at 09:00 h. Water was provided ad
libitum to the fasted mice (43).
This research was approved by the local ethics committee
and met the criteria for animal experiments.
Sequencing analysis
Genotyping was performed to confirm and genetically
characterize the lit/lit, lit/+, and wt/wt mice. The mice
were genotyped by the PCR amplification of tail DNA
isolated using the standard phenol protocol of our labora-
tory (44,45). Two primers, 59-TGAGCTTGCATGTCTTCA-
GG-39 and 59-GGGATTAGACCAGCCAGTGA-39 (anneal-
ing temperature, 60 C˚), were used to amplify the gene
region of the ghrhr Asp60Gly mutation that results in the
little mouse phenotype (24). The mutation analysis was
performed by automated sequencing using the Big Dye
Terminator v3.1 (310 Sequencer, Applied Biosystems, Foster
City, CA, USA).
The forward and reverse strands were analyzed in
duplicate DNA samples. Two sequencing editor software
programs (Gene StudioTM Professional Edition, Suwanee;
and Mutation Surveyour, Softgenetics, PA, USA) were used
to identify DNA abnormalities.
Preparations and injections
GHRP-2 (200 mg/ml; lot KP102-HQ007; Pramorelin:
D-alanyl-3-(2-naphthyl)-D-alanyl-L-alanyl-L-tryptophyl-D-
phenylalanyl-L-lysinamide dihydrochloride) was obtained
from Fujisawa USA, Inc. (Deerfield, IL). The mice were
given intra-peritoneal (i.p.) injections and weighed.
Depending on the experimental design, blood samples
were collected from the orbital sinus for the measurements
of GH, IGF-I, leptin, or ghrelin.
Immunoassays
The mouse GH (mGH) serum levels were determined by a
highly sensitive in-house specific RIA using reagents obtained
from Dr. A. F. Parlow of the National Hormone and Pituitary
Program (NHPP, Torrance, CA) (46). All samples were
assayed in duplicate. In each assay, pools of wt/wt C57BL
and lit/lit mice sera were used as internal controls. Eight mice
from each strain were used, and the pooled (n = 8) serum level
of GH was 1.3¡0.7 ng/ml in the lit/lit mice and 6.5¡1.8 ng/
ml in the wt/wt C57BL mice. The initial GH levels in the lit/+
mice were not significantly different from those in the wt/wt
C57BL mice, probably because of the number of animals. The
sensitivity of the GH assay, which was performed via a
delayed tracer addition, was 0.25¡0.15 ng/ml as calculated
according to Rodbard’s definition (47). The inter-assay
coefficient of variation was less than 10%.
Levels of IGF-I were determined in duplicate using a rat
IGF-I RIA kit (DSL-2900, Diagnostic Systems Laboratories
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Inc., Webster, Texas, USA) with a minimum detection level
of 21 ng/ml and measurable concentrations ranging from
150 to 4,500 ng/ml.
Leptin levels were determined using a rat leptin RIA kit
(Linco Research Inc., St. Charles, MO, USA) with a
minimum detection value of 0.2 ng/ml and a measurable
concentration range of 0.2-12.8 ng/ml.
Total ghrelin (octanoylated + desoctanoylated)(48) levels
were determined using a rat ghrelin RIA kit (Phoenix
Pharmaceuticals Inc., Belmont, CA, USA) with a sensitivity
of ,5.4 pg/tube and a range of 1-128 pg/tube. Active
ghrelin (octanoylated) levels were determined using the
Linco Research kit (St. Charles, MO). For these measure-
ments, blood samples were collected in tubes containing
0.78 mg K2EDTA (250-500 ml blood/tube), kept on ice and
spun in a refrigerated centrifuge. PMSF (0.1 mg/ml plasma)
and 1 M HCl (50 ml/ml plasma) were added to the plasma
samples. The samples were kept frozen at -70 C˚ until the
ghrelin levels were measured. For the active ghrelin kit, the
intra- and inter-assay coefficients of variation were 6.5-9.5%
and 9.6-16.2%, respectively. For the total ghrelin kit, the
intra- and inter-assay coefficients of variation were ,10%
and ,15%, respectively.
Study design
Two groups of age-matched, wild-type (+/+) C57BL mice
were initially injected i.p. with either 1 mg (32 animals/
group) or 10 mg (18 animals/group) GHRP-2, and blood
samples for the GH measurements were collected at
different times up to 1 h after injection. Three mice were
used for each time point, and the blood was withdrawn only
once before the animals were sacrificed. In a pilot study,
10 mg GHRP-2 was administered i.p. to 2-3 lit/lit, lit/+ and
(wt/wt) mice (n = 18 animals/group), and the GH response
was measured at different times up to 1 hour after injection
to assess the effects of dose and timing.
An independent two-week study was performed with lit/
lit mice treated daily with 10 mg GHRP-2 i.p. per mouse
(n = 6 mice for the control and n = 8 mice for the experi-
mental group). The body weight was measured, and blood
was drawn every 3-4 days to measure the GH, IGF-I and
leptin levels. As previously described, the body weight was
measured using a precise, highly sensitive methodology
(40). Briefly, animal body weights were measured daily
throughout the entire experiment and then used to calculate
individual growth curves; the slopes of the growth curves
were then used as response parameters. For the lit/lit
mice, the acceptable daily weight variation in the last ten
days before each assay (pre-assay period) was within
0.0025¡0.0045 g/day (36,40). Thus, approximately 10% of
the homozygous dwarf mouse population was rejected. Our
criteria for selecting the lit/lit mice were based on the
growth curves of the homozygous (lit/lit) and heterozygous
(lit/+) mice of the C57BL/6J strain, which had already been
established in a previous study (36) and further confirmed
by the genotyping performed here.
To evaluate and compare the areas under the curve of the
hormonal values, an arbitrary unit of concentration (ng/ml/
time (min)) was defined.
Statistics
To analyze the leptin levels and hormonal responses as
measured by the area under the curve (AUC) data, a two-
way analysis of variance (ANOVA) was performed with
time and treatment as the independent variables. Student’s
t-test with Bonferroni’s adjustment was used for all values
obtained after initiation of treatment. In all other measure-
ments, Student’s paired t-test was used to evaluate the
significance of differences. p,0.05 was considered to be
significant.
RESULTS
ghrhr mutation analysis
DNA was extracted from a blood sample of a lit/lit
mouse using routine methods described elsewhere (44,45).
PCR using previously reported primers was performed,
followed by the sequence analysis of the ghrhr gene.
A germline homozygous ghrhr Asp60Gly mutation was
confirmed in the lit/lit mouse, whereas a heterozygous
ghrhr Asp60Gly mutation was verified in the lit/+ litter-
mates. Conversely, wild-type (+/+) C57BL/6J mice did not
harbor this germline mutation (Figure 1). These data
confirmed the genotypes of the three mice lineages used
in the present study, respectively: +/+, Asp60Asp; lit/+,
Asp60Gly and lit/lit, Gly60Gly (Figure 1).
Basal GH and IGF-I levels in normal and
homozygous mice
The mean basal mGH levels in the 18 homozygous lit/lit
mice (1.16¡0.97 ng/ml; range, 0.28-4.0 ng/ml) were signifi-
cantly lower than those observed in the 46 wild-type (+/+)
controls (5.36¡2.60 ng/ml; range, 1.05-14.0 ng/ml; p,0.001)
or their 12 heterozygous (lit/+) littermates (6.60¡2.35 ng/
ml; range, 4.25-11.5 ng/ml; p,0.001). Furthermore, the basal
GH concentrations observed in the lit/+ and +/+ mice did
not differ significantly.
The basal serum IGF-I value in the 8 lit/lit mice
(231¡103 ng/ml; range, 120-420) was clearly lower than
that in the 8 +/+ controls (473¡104 ng/ml; range, 330-
560 ng/ml; p,0.001).
Response of GH to acute GHRP-2 administration
It was initially shown that the increase of GH in the
C57BL wild type control mice in response to 1 mg GHRP-2
was significantly less (,two-fold increase over basal levels)
than the increase in response to 10 mg of i.p. GHRp-2 (24-
fold increase over baseline values; p,0.05). Thus, the 10-mg
GHRP-2 dose was selected for the assessment of the GH
responses in the three groups of mice (+/+, lit/+ and lit/lit).
The mean peak GH response in the control group (+/+)
was 163 ng/ml, and it occurred 10 min after the adminis-
tration of GHRP-2 with a 24-fold increase over the baseline
levels (Figure 2). In the lit/+ and lit/lit mice, there was a
significant GH response to GHRP-2 at 5-10 min. Twenty
minutes after GHRP-2 injection, GH levels returned to the
baseline values.
These data indicate that the GH response to 10 mg GHRP-
2 (9.3¡1.5 ng/ml; range 8-11 ng/ml) observed in the
homozygous lit/lit mice was significantly higher than that
in the saline-injected lit/lit mice (1.04¡1.15 ng/ml;
p,0.001). Furthermore, the response of GH to GHRP-2 in
the lit/lit mice was significantly lower than that observed in
the heterozygous (lit/+) littermates (9.3¡1.5 ng/ml vs.
34.5¡9.7 ng/ml; p,0.01) or in the wild type (+/+) mice
(163¡46 ng/ml; p,0.005). Thus, the GH response to GHRP-
2 in the lit/+ mice was intermediate to those observed in the
lit/lit and +/+ mice (Figure 2).
CLINICS 2012;67(3):265-272 GH response to GHRP-2 in Little mice
Peroni CN et al.
267
The absolute GH increases over the baseline in the lit/lit,
lit/+, and +/+ mice were 8.3, 28.8, and 156 ng/ml,
respectively, which confirms the marked differences in
GH secretion among the three studied mice strains. The
increase in the GH level over the baseline following the
acute administration of 10 mg GHRP-2 did not differ
significantly between the lit/lit and lit/+ mice (8.9- vs. 6.1-
fold; p.0.05). However, the increase in GH in response to
GHRP-2 was significantly decreased in the lit/lit (p,0.005)
and lit/+ mice (p,0.01) compared with the controls. The
individual areas under the curve (AUCs) of the serum GH
in response to the acute administration of GHRP-2 further
confirmed the significant differences between the GHRP-2-
and saline-treated lit/lit mice (Figure 3).
Responses to the two-week administration of
GHRP-2
As expected, a marked increase in body weight was
observed in the lit/lit mice when 10 mg GHRP-2 was i.p.
injected (49) once a day for two weeks in comparison to
injection of the control vehicle (p,0.02; Figure 4). However,
GH and IGF-I levels did not significantly increase during
the two-week administration of GHRP-2 (data not shown).
Furthermore, markedly elevated (p,0.005) leptin levels in
the lit/lit mice were observed on day 15 of the GHRP-2
treatment.
Serum ghrelin and leptin levels
The concentrations of plasma acyl ghrelin and total (acyl +
deacyl) ghrelin, which may have independent and inter-
related biological actions, and the concentrations of serum
leptin in the +/+, lit/+, and lit/lit mice in the fasted and fed
state are shown in Table 1. In the fasted state, the mean
plasma acyl ghrelin and total ghrelin levels in the lit/lit
mice were significantly lower (by 78.9% and 37.6%,
respectively) than in the +/+ mice. The heterozygous lit/+
mice also had significantly lower levels of fasting acyl
ghrelin and total ghrelin (by 80.5% and 44.9%, respectively)
compared with the controls. In the lit/lit mice, the plasma
acyl ghrelin in the fed state was 93.8% higher than in the
fasted state. Conversely, in the wild-type mice, the plasma
acyl ghrelin was 82.5% lower (p,0.001), and total ghrelin
was 61% lower (p,0.001) in the fed state than in the fasted
state. The difference in the fed-state plasma acyl ghrelin
levels between the two groups (157¡70 pg/ml for +/+ mice
vs. 67¡18 pg/ml for lit/lit) was significant (p,0.05).
Furthermore, the total ghrelin levels were 23.4% higher in
the fasted state than in the fed state for the lit/lit mice.
Figure 1 - The germline ghrh-r Asp60Gly mutation analysis was performed by PCR amplification and direct automated sequencing. The
chromatogram traces show the GAT/GAT (wild-type), GAT/GGT (heterozygous mouse) and GGT/GGT (little mouse) statuses, thus
characterizing the genotype of the three mice strains used in this study. The forward and reverse traces are shown in the top and
bottom panels, respectively.
Figure 2 - Mouse GH (mGH) serum concentrations were
determined by a sensitive RIA method (detection limit, 0.25 ng/
ml). Shown here are the mGH increases after the acute
administration of 10 mg GHRP-2 in lit/lit, lit/+ and +/+ mice as
well as the saline injection of lit/lit mice. Three animals were used
for each time point only once each and then sacrificed. In total,
18 animals were used for each of the four observations, and 72
animals were used in total.
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The serum leptin levels of the fasted lit/lit mice were
348% higher than those in the fasted +/+ mice (p,0.005).
The fasted lit/+ mice also differed from the lit/lit (50%
lower, p,0.02) and +/+ mice (123% higher, p,0.005).
Moreover, in the lit/lit mice, the serum leptin levels in the
fed state decreased by 35% compared with the fasted state
(p.0.05). Additionally, leptin levels in the fed lit/+ and +/+
fed mice were 37% and 16% higher than in the fasted
animals, respectively (p.0.05).
DISCUSSION
Several spontaneous homozygous germline mutations in
mice that result in the deficiency of pituitary hormones and
dwarfism have been documented (34). Thus, the phenotypes
of the Ames dwarf mice result from mutations in the Prop1
gene and present a congenital deficiency of multiple
pituitary hormones, including GH (50). In addition, Snell
dwarf mice with mutations in the pit gene have dwarfism
arising from GH deficiency, hypothyroidism, and infertility
(51). Furthermore, the little mice phenotype results from
homozygous mutations in the ghrh-r gene (33). Equivalent
germline homozygous mutations in the PROP1, PIT, and
GHRH-R genes have been reported in humans presenting
with severe short stature (37,52,53).
GHRH-R mutations have been specifically suggested to
cause the absence of a GH response to GHRP-2 in humans
(54). However, several other studies documented a limited
but statistically significant increase in GH after the admin-
istration of GHRP-2 to these patients (28-30). Similarly, it
has been suggested that the little mouse is resistant to the
action of GHRP-2 and does not present an increase in GH
after the administration of this peptide (41). Thus, the main
goal of the present study was to investigate whether little
mice have an absolute resistance to the action of GHRPs,
as previously described, or if they present a statistically
significant GH response to one of the GHRPs, i.e., GHRP-2,
as observed in humans. To detect minor GH variations in
the serum, we used an improved mGH method to better
discriminate possible GH increases after the administration
of GHRP-2.
To our knowledge, no other paper to date has specifically
re-investigated this issue in little mice. Of note, complete
GH resistance to GHRP-2 in ghrh-knockout mice has been
documented. However, the ghrh-knockout mice and little
mice have mutations in different genes, although their
phenotypes are similar. Furthermore, different GH methods
and experimental conditions may have influenced these
apparently contradictory results.
GH responses to GHRP-2
The development and function of somatotroph cells are
GHRH-dependent (1), as indicated by our findings of a
limited GH response to acute GHRP-2 administration in
lit/lit mice carrying a homozygous mutation in ghrhr.
Assuming that ghrhr is completely inactive in lit/lit mice
(39), our present findings indicate that at least some GHRH-
independent GHS-GH release occurs through the activation
of the GHS-R.
In addition to mature GHRH-dependent somatotrophs,
GH-producing stem cells have been found in the pituitary
glands of lit/lit mice and in 60-day-old adult mice (26).
Figure 3 - Serum mGH responses to the acute administration of 10 mg GHRP-2 (or saline, SAL for lit/lit mice) in the lit/lit, lit/+, and +/+
mice expressed as the areas under the curve (AUCs). An arbitrary unit (ng/ml/min) was used to allow evaluation of the AUC. The animal
experiments are as shown in Figure 2.
Figure 4 - The weight gain assay upon the chronic administration
of 10 mg/animal/day GHRP-2 in the lit/lit mice; eight animals were
used in this experiment (n=8). The control group was injected
with saline; six lit/lit mice were used in this experiment (n=6).
The mean and standard error of the mean intervals are shown.
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However, it is not known whether GHRP-2 and/or ghrelin
act as a trophic factor for the GH-producing stem cells
independently of the pituitary action of GHRH.
The previously reported lack of a GH response in lit/lit
mice to another type of GHS, GHRP-6 (41), may be related to
the use of a less sensitive GH assay (10 ng/ml vs. 0.25 ng/ml
for our assay). Furthermore, GHRP-2 has a greater biological
potency (approximately six-fold greater) than GHRP-6 for
triggering the release GH (14-16). The absence of GH
responses to GHRP-6 was also initially suggested in humans
with a Glu72Stop GHRH-R mutation (42). However, several
other studies have documented the presence of a statistically
significant, although impaired, GH response to GHRP-2 in
patients with genetic short stature who harbor a severely
truncated GHRHR gene (28-30).
Furthermore, neither acute nor chronic GH elevations
were noticed in ghrh-knockout mice, and it was concluded
that GHRP-2 has a growth-stimulating effect that augments
the response induced by JI-38 (55,56). However, it is
important to note that a) knockout mice and animals
harboring similar or even equivalent spontaneous germline
mutations may behave differently; b) the mGH methods
used to study the little mice and knockout mice could be
different; and c) different experimental designs were used in
these studies (28-30,55,56).
The intermediate GH responses to GHRP-2 in the lit/+
mice may be the result of qualitative and/or quantitative
differences in the somatotroph cells, although further
research on this topic should be conducted to confirm these
findings. These data may suggest a genetic dosage effect on
somatotroph cell function, which would become more
impaired as a function of age. Similarly, a genetic dosage
effect was previously proposed for cases carrying a
mutation in the GHRHR gene (52).
Importantly, our GH RIA method was able to detect the
presence of very low GH levels (,0.25 ng/ml) in little mice
with acceptable precision; similar data are seldom available in
the literature. GH kits with lower sensitivities have been used
by others. However, no other reports were found that
addressed the serum GH levels of lit/lit mice obtained by a
specific homologous RIA. Cheng et al. reported serum GH
levels of 0.61¡0.09 ng/ml in male and female lit/lit mice and
8.50¡0.75 ng/ml and 2.85¡0.33 ng/ml in male and female lit/
+ mice, respectively. Marmary et al. reported serum GH levels
of 1.08¡0.06 ng/ml and 20.35¡22.9 ng/ml in Snell dwarf mice
and their control littermates, respectively (58). High estimates of
the absolute level of serum GH determined using a hetero-
logous rat GH RIA have also been reported (59,60).
Growth following GHRP-2 administration
In this study, a definite increase in the body weight of
little mice was observed after the administration of GHRP-2.
These findings are in agreement with other studies that
documented a significant body weight gain in ghrh-knock-
out mice treated with GHRP-2 and in mice after the
administration of ghrelin, which shows that both peptides
induce adiposity in these animals (61). Of note, Alba et al.
did not observe an increase in the longitudinal growth of
ghrh-knockout mice during a six-week treatment with
GHRP-2 at a dose of 10 mg injected subcutaneously (s.c.)
twice a day, which confirmed the pivotal role of GHRH
in GH secretion and subsequent body growth (48).
Additionally, a chronic six-week treatment with 10 mg s.c.
GHRP-2 did not increase the acute GH response (30-min).
This apparent discrepancy with our findings may have
resulted from differences in the time of blood collection or
GH assay sensitivity, different methods of drug adminis-
tration (s.c. vs. i.p.), or a combination of these factors.
Leptin and ghrelin levels in the lit/lit mice
We also evaluated whether GHRP-2 would influence
leptin and ghrelin levels.
The fasting levels of acyl ghrelin and total ghrelin were
higher in the wild-type +/+ mice than in the fed mice (61-
63). The physiological regulation of the plasma ghrelin (i.e.,
its increase and decrease in the fasting and fed states,
respectively) was different in the lit/lit mice. This finding
may be the result of a lack of effect of the action of GHRH
and its inactive GHRH-R, although this hypothesis should
be tested further.
High basal serum leptin levels and an additional increase
after prolonged GHRP-2 administration in lit/lit mice have
also been observed in mice treated with ipamorelin (34).
These findings are considered to reflect the increased
adipose tissue mass in GH-deficient mice and the adipo-
genic effect of GHRP-2 and ghrelin (61-63).
To investigate the lipogenic effects of these peptides in
mice, the doses of GHRP-2 used in the present study were
similar to those used by Tschop et al. and to the GHRP-6
doses used by Jansson et al. and Lall et al. (38,49,61).
However, based on body weight, such doses were propor-
tionally much higher than those tested in humans with a
GHRH-R mutation, which could reflect interspecies differ-
ences in the sensitivity to GHSs (61).
Our limited data on the octanoyl ghrelin (ghrelin) and
serum leptin levels in fed vs. fasted (17 h) wild-type (+/+)
and lit/lit mice (-/-) may suggest dysfunctional relation-
ships between these two metabolic hormones. As expected,
the plasma ghrelin levels were normal in the fed wild-type
mice and elevated in the fasted wild-type mice, although the
opposite effect was also observed, as ghrelin and leptin
were elevated in the fed state and did not further increase in
the fasted state. Additionally, the results in the lit (+/-) mice
partially paralleled those obtained in the lit (-/-) mice in that
Table 1 - The plasma ghrelin and serum leptin concentrations in fed and 16-hour-fasted little (lit/lit), heterozygous (lit/
+), and wild-type (+/+) mice.
Mouse strain Bioactive ghrelin (pg/ml) Total ghrelin (pg/ml) Leptin (ng/ml)
fed fasted fed fasted fed fasted
+/+ 67 ¡ 18.2(6) 384 ¡ 100 1272 ¡ 410(7) 3261 ¡ 222 2.70 ¡ 0.32(8) 2.32 ¡ 0.60
lit/+ 85 ¡ 14.2(NS) 75 ¡ 3.0(1) 1538 ¡ 96.0(NS) 1796 ¡ 540(2) 7.09 ¡ 5.0(9) 5.18 ¡ 0.72(2)(5)
lit/lit 157 ¡ 70(4) (10) 81 ¡ 21.8(2) 2513 ¡ 384(11) 2036 ¡ 706(3) 6.78 ¡ 3.74(12) 10.40 ¡ 2.62(2)
All measurements are derived from the average ¡ SD of n=4 animals/group.
(1) p,0.001, (2) p,0.005, (3) p,0.02, (4) p,0.05, NS = non-significant, all compared to +/+; (5) p,0.02 compared to lit/lit; (6) p,0.001 compared to fasted;
(7) p,0.001 compared to fasted; (8)-(12) all NS compared to the corresponding fasted animals.
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the plasma ghrelin levels did not increase with fasting, and
during fasting, the serum leptin levels remained elevated in
the fed and fasted lit (+/- and -/-) mice. However, the
limited number of studied animals prevented further
conclusions from being drawn. Finally, the measurement
of total ghrelin as an indicator of octanoyl ghrelin levels may
be problematic. Although the total and octanoylated ghrelin
levels may partialy parallel each other, this agreement
becomes less evident under pathophysiological conditions,
such as in the present mouse study. Increasing evidence
supports the biological activity of the desoctanoyl ghrelin
molecule and thus in turn supports the measurement of the
plasma desoctanoylated ghrelin levels by a specific assay,
such as that published by Akamizu et al. (64).
In conclusion, our findings are the first to document the
presence of statistically significant increases in GH follow-
ing the administration of GHRP-2 in little mice. The data
give further support to a direct action of GHRP-2 in the
pituitary glands of little mice. Furthermore, the hetero-
zygous lit/+ mice may have subtle disturbances in their
GHRH/GHRH-R/GH axis, which suggests a genetic
dosage effect, although additional data are needed to
confirm this conclusion.
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